Salix Pharmaceuticals 8-K Other Events

Exhibit 99.1

FOR IMMEDIATE RELEASE

Contact:	Adam C. Derbyshire	Mike Freeman
	Senior Vice President and	Executive Director, Investor Relations and
	Chief Financial Officer	Corporate Communications
	919-862-1000	919-862-1000

SALIX PHARMACEUTICALS ANNOUNCES

3Q2004 FINANCIAL RESULTS

CONFERENCE CALL AND WEBCAST

RALEIGH, NC, November 2, 2004 - Salix Pharmaceuticals, Ltd. (Nasdaq:SLXP) today announced that the company will report third quarter ended September 30, 2004 financial results before the market opens on Tuesday, November 9, 2004.

The Company will host a conference call at 9:00 a.m. ET, on Tuesday, November 9, 2004. Interested parties may access the conference call by way of web cast or telephone. The live web cast will be available athttp://www.salix.com. The web cast will be archived on the Company’s web site through November 15.

The telephone numbers to access the conference call are (800) 946-0741 (U.S. and Canada) or (719) 457-2649 (international.) The access code for the call is 952908. A replay of the call will be available from 12:00 noon ET, November 9, through November 15. The telephone numbers to access the replay of the call are (888) 203-1112 (U.S. and Canada) or (719) 457-0820 (international.) The access code for the replay is 952908.

Salix Pharmaceuticals, Ltd., headquartered in Raleigh, North Carolina, develops and markets prescription pharmaceutical products for the treatment of gastrointestinal diseases. Salix’s strategy is to in-license late-stage or marketed proprietary therapeutic drugs, complete any required development and regulatory submission of these products, and market them through theCompany’s 100-member gastroenterology specialty sales and marketing team. Salix trades on the Nasdaq National Market under the ticker symbol “SLXP”.

For more information please contact the Company at 919-862-1000 or visit our web site atwww.salix.com. Information on our web site is not incorporated in our SEC filings.

2